# FDA 483 - Wilber W. Su, MD - February 27, 2026

Source: https://www.keypedia.com/records/483/wilber-w-su-md/0597bb02-80cc-48c4-9398-bc58876f47f0

> FDA 483 for Wilber W. Su, MD on February 27, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Wilber W. Su, MD
- Inspection Date: 2026-02-27
- Product Type: drugs
- Office Name: Denver District Office
- Summary: Wilber W. Su, MD, a clinical investigator in Phoenix, AZ, was cited for failing to conduct an investigation according to the signed agreement and investigational plan. The inspection revealed issues with enrolling ineligible subjects, incomplete baseline assessments, and a lack of documentation for protocol deviations. These findings indicate significant non-compliance with study protocols.

## Related Officers

- [Jose A. Leyva](https://www.keypedia.com/people/jose-a-leyva/0c0ffdd3-cd41-4e30-bf61-e96f62a58921)

Company: https://www.keypedia.com/companies/wilber-w-su-md/e13f51b0-59c4-4c6f-a8da-0d4b4e858b6a

Office: https://www.keypedia.com/offices/denver-district-office/93b79063-390c-4759-af6c-5da7e388face